Immunotherapy of gastric cancer: Present status and future perspectives

Table 1 Food and Drug Administration-approved immunotherapy options for gastric cancer

	Target	Action	Approved for
Targeted antibodies
Ramucirumab (Cyramza®)	VEGF/VEGFR2 pathway	Inhibits tumor blood vessel growth	Subsets of patients with advanced GC
Trastuzumab (Herceptin®)	HER2 pathway	Inhibition	Advanced HER2- + GC
Trastuzumab deruxtecan (Enhertu®): Antibody-drug conjugate	HER2 pathway	Inhibition	Subsets of patients with advanced GC
Immunomodulators
Dostarlimab (Jemperli)	PD-1/PD-L1 pathway	Checkpoint inhibitor	Advanced GC that has dMMR
Nivolumab (Opdivo®)	PD-1/PD-L1 pathway	Checkpoint inhibitor	Subsets of patients with advanced GC
Pembrolizumab (Keytruda®)	PD-1/PD-L1 pathway	Checkpoint inhibitor	Subsets of patients with advanced GC

dMMR: DNA mismatch repair deficiency; GC: Gastric cancer; HER2: Human epidermal growth factor receptor 2; PD-1: Programmed cell death protein 1; PD-L1: Programmed death-ligand 1; VEGF: Vascular endothelial growth factor.